Erivedge

RSS

vismodegib

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Erivedge. It explains how the Agency assessed the medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Erivedge.

For practical information about using Erivedge, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 22/06/2022

Authorisation details

Product details
Name
Erivedge
Agency product number
EMEA/H/C/002602
Active substance
vismodegib
International non-proprietary name (INN) or common name
vismodegib
Therapeutic area (MeSH)
Carcinoma, Basal Cell
Anatomical therapeutic chemical (ATC) code
L01XX43
Publication details
Marketing-authorisation holder
Roche Registration GmbH
Revision
14
Date of issue of marketing authorisation valid throughout the European Union
12/07/2013
Contact address

Emil-Barell-Strasse 1
79639 Grenzach-Wyhlen
Germany

Product information

01/07/2021 Erivedge - EMEA/H/C/002602 - R/0050

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antineoplastic agents

Therapeutic indication

Erivedge is indicated for the treatment of adult patients with:
- symptomatic metastatic basal cell carcinoma
- locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy

Assessment history

How useful was this page?

Add your rating
Average
1 rating